CSIMarket
 
Innovation1 Biotech Inc   (MYYZ)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 20
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Innovation1 Biotech Inc
Innovation1 Biotech Inc is a biotechnology company that focuses on developing innovative solutions for the healthcare industry. The company specializes in the research and development of advanced therapies, medicines, and medical devices to address various medical conditions. With a team of highly skilled scientists and researchers, Innovation1 Biotech Inc aims to revolutionize medical treatments and improve patient outcomes through cutting-edge technologies and scientific advancements. The company is committed to bringing transformative healthcare products to market and making a positive impact on society.


   Company Address: 7 Grand View Avenue Somerville 2143 MA
   Company Phone Number: 447-8299   Stock Exchange / Ticker: MYYZ
   MYYZ is expected to report next financial results on May 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Innovation1 Biotech Inc

The ascending corporation from the Major Pharmaceutical Preparations market the Innovation1 Biotech Inc issued the financial period ending fourth quarter of 2023, numbers

In the competitive and fast-paced world of the Major Pharmaceutical Preparations industry, it is often the large companies that grab the headlines. However, there are a few smaller entities that deserve attention for their promising performance. Innovation1 Biotech Inc is one such company that has recently revealed its impressive operating surplus for the fourth quarter of 2023.
Innovation1 Biotech Inc reported an operating surplus of $0.201329 million for the fourth quarter of 2023, a significant improvement from the operating surplus of $-37.291081 million in the same period the previous year. This revelation is even more noteworthy considering the absence of usual references in the industry.

Innovation1 Biotech Inc

Innovation1 Biotech Inc Surprises Stock Market with Genuine Rise in May 2023 Report, Despite Operating Deficit of $-0.203614 Million


As an observer of the financial markets and an avid investor, it is fascinating to delve into the financial results of companies and uncover the nuances that shape their trajectory. Today, we will focus on Innovation1 Biotech Inc., a major player in the pharmaceutical industry, and interpret their recent financial results.
Shareholders of Innovation1 Biotech Inc. anticipated stability and perhaps even modest growth during the earnings cycle of fiscal March to May 31, 2023. Unfortunately, their hopes were met with disappointment as the company experienced an operating deficit of $-0.203614 million during the same period. This deficit serves as a stark contrast to the performance of the company's top-line.

Innovation1 Biotech Inc

Innovation1 Biotech Inc Faces Significant Deterioration in Business Performance during Second Quarter of 2023 Earnings Season, Shaking Industry Confidence

The stock market is a fascinating and often unpredictable realm, where investors eagerly await the release of earnings reports to gauge the performance of various entities. As we stride through the earnings cycle of fiscal December to February 28, 2023, numerous companies have unveiled their financial results. Among these, several constituents of the Major Pharmaceutical Preparations sector have captured the attention of investors and analysts alike.
Today, it is with great interest that we delve into the financials of Innovation1 Biotech Inc, a prominent player in the healthcare industry. The company recently disclosed an operating deficit of $-0.736281 million for the financial interval closing on February 28, 2023. While this may seem like a setback, it is important to view this figure within the larger context of the firm's performance.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com